Barozzi et al (2002) reported that TGF-α, MMP-2 and IGF-II seem to be suitable candidates for a selective panel of markers designed to provide significant information with respect to the current pathologic staging system for patients with colorectal carcinoma. The gene discussed is IGF2; the disease is colorectal carcinoma.